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Summary
Mucosal-associated invariant T (MAIT) cells are donor-unrestricted lym-
phocytes that are surprisingly abundant in humans, representing 1–10%
of circulating T cells and further enriched in mucosal tissues. MAIT cells
recognize and are activated by small molecule ligands produced by
microbes and presented by MR1, a highly conserved MHC-related anti-
gen-presenting protein that is ubiquitously expressed in human cells.
Increasing evidence suggests that MAIT cells play a protective role in
anti-bacterial immunity at mucosal interfaces. Some fungi are known to
produce MAIT-activating ligands, but the role of MAIT cells in fungal
infections has not yet been investigated. In viral infections, specifically
HIV, which has received the most study, MAIT cell biology is clearly
altered, but the mechanisms explaining these alterations and their clinical
significance are not yet understood. Many questions remain unanswered
about the potential of MAIT cells for protection or pathogenesis in infec-
tious diseases. Because they interact with the universal, donor-unrestricted
ligand-presenting MR1 molecule, MAIT cells may be attractive
immunotherapy or vaccine targets. New tools, including the development
of MR1-ligand tetramers and next-generation T-cell receptor sequencing,
have the potential to accelerate MAIT cell research and lead to new
insights into the role of this unique set of lymphocytes in infectious dis-
eases.
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Introduction
What are MAIT cells and what is known about their
phenotype and function?
Mucosal associated invariant T (MAIT) cells are ab T
cells with a limited T-cell receptor (TCR) repertoire that
uses mostly TRAV1-2 recombined with a biased set of
TRAJ genes (primarily TRAJ 33, TRAJ 12 and TRAJ 20)
and TCR-b chains.1–4 MAIT cells are uniquely activated
by small molecule vitamin B metabolites presented by the
ubiquitously expressed and non-polymorphic MHC-class
1-like molecule, MR1.5–9 Circulating MAIT cells express
certain phenotypic markers that have been used in vary-
ing combinations to identify them in human specimens:
TRAV1-2, IL-18Ra, IL-23/12Ra, and high expression of
both CD26 and CD161.10,11 Use of different phenotypic
definitions of MAIT cells has limited comparability of
findings in the field. The recent development of ligand-
loaded MR1 tetramers promises to aid in consistent defi-
nitions.12 At this point it appears that MR1 tetramers
loaded with 5-(2-oxopropylideneamino)-6-D-ribitylami-
nouracil (5-OP-RU) stain the vast majority of MR1-reac-
tive cells in the peripheral blood of healthy humans,
though whether additional classes of MAIT cell activating
MR1 ligands exist is a topic of ongoing active investiga-
tion.13
MAIT cells comprise 1–10% of circulating CD3+ T cells
in healthy adults.14,15 Although their distribution in tis-
sues has not been thoroughly investigated, they have been
found to be enriched in the gastrointestinal tract, liver
and airway.10,16–19 MAIT cell activation can result from
either TCR-dependent signalling (triggered by ligand pre-
sented on MR1 by antigen-presenting cells) or from
TCR-independent cytokine signalling.20–23 Like other ‘in-
nate-like’ lymphocytes including invariant natural killer T
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cells and natural killer cells, MAIT cells respond rapidly
to activation by producing cytokines and cytolytic prod-
ucts. Upon TCR-dependent or TCR-independent activa-
tion, MAIT cells produce interferon-c (IFN-c), tumour
necrosis factor-a (TNF-a), cytolytic products (perforin,
granulysin and granzymes) and degranulate (exposing
CD107a to the cell surface).10,11,24–26 Interleukin-12 (IL-
12) and IL-18 have been shown to induce MAIT cell pro-
duction of IFN-c in the absence of TCR signalling.22 Both
IL-15 and IL-7 have each been shown to license MAIT
cells for enhanced production of TCR-activated pro-
inflammatory cytokines and cytolytic products.23,26,27
MAIT cells express the transcription factors promyelocytic
leukaemia zinc finger protein (PLZF) and RAR-related
orphan receptor (RORcs) and do not develop in Rorc/
mice.26,28 Multiple groups have noted that circulating
MAIT cells produce IL-17 upon PMA/ionomycin stimula-
tion but not TCR-triggered stimulation.10,17,26,29 A recent
study found that compared with peripheral blood MAIT
cells, MAIT cells from the female genital tract produced
significantly more IL-17 and IL-22 and significantly less
IFN-c or TNF-a when stimulated with either bacteria or
PMA/ionomycin.30 The significance of IL-17 production
by MAIT cells in vivo requires further investigation.
The MAIT cell biology field is still in its early stages.
Despite recent increased interest and increasing num-
bers of papers that examine MAIT cells in human dis-
eases and animal models of diseases, many questions
remain unanswered about the function of this immune
subset in the healthy and perturbed immune system.
Here we review the rapidly evolving literature concern-
ing the role of MAIT cells in infectious diseases and
highlight areas of evolving consensus and remaining
gaps in knowledge.
MAIT cells in infectious diseases
In their structure and function MAIT cells appear to
bridge the innate and adaptive immune system. They are
ab T cells whose TCRs have restricted diversity and rec-
ognize small molecule microbial metabolites. In the pro-
cess of synthesizing riboflavin, many bacterial and fungal
organisms, both pathogens and commensals, produce
small molecule intermediates that have the capacity to
directly activate MAIT cells.9,31,32 It has been hypothe-
sized that these small molecule metabolites may comprise
a novel class of microbial ‘danger’ signals that alert the
host’s immune system – via MAIT cells – to the presence
of non-host products. However, the exact role that this
class of unique T cells plays in the detection of and
response to these organisms in human disease is
unknown. Data from in vitro experiments, animal models
of disease and observational human cohorts provide some
indication of the role that MAIT cells may play in infec-
tions with MR1-ligand producing organisms (bacteria
and fungi) and in infections with non MR1-ligand produ-
cing organisms (viruses). The role that MAIT cells play in
other classes of human infectious disease – including
parasitic infections – is completely unknown.
The role of MAIT cells in bacterial and
mycobacterial infections
Insights from in vitro experiments
Upon exposure to bacteria that produce MR1 ligands,
MAIT cell clones cultured from human peripheral blood
and polyclonal MAIT cell populations isolated from human
peripheral blood (TRAV1-2+ CD161++) produce pro-
inflammatory cytokines (TNF-a, IFN-c) and cytolytic prod-
ucts (granzymes, granulysin, perforin).11,20,21,24–26 This is
true when MAIT cells are exposed to bacterial preparations
directly (fixed Escherichia coli, Mycobacterium tuberculosis
lysate) or when MAIT cells are added to cultured cells that
have been experimentally infected (with E. coli, Salmonella
typhimurium, Mycobacterium smegmatis, M. tuberculo-
sis).13,20,33 The production of cytokines and cytolytic prod-
ucts by MAIT cells in these experiments appears to largely
depend on TCR signalling triggered by MR1-presented
ligand and can be augmented by pre-conditioning with a
number of cytokines including IL-12, IL-23, IL-15 and
IL-7.22,23,26,27 Adding MAIT cells to infected cells can result
in lysis or apoptosis of the infected cells.1,25,26 Moreover,
MAIT cells have the ability to decrease mycobacterial bur-
den when added to experimentally infected cell cultures.
Chua et al.34 showed that the addition of polyclonal MAIT
cells to macrophages experimentally infected with Mycobac-
terium bovis BCG inhibited bacterial growth. Lepore et al.1
demonstrated that MAIT cell clones with typical (TRAV1-
2/TRAJ33) and atypical (TRAV1-2/TRAJ12) TCRs
decreased M. bovis BCG load in infected macrophages. In
sum, these in vitro experiments show that bacterially pro-
duced MR1 ligand activates MAIT cells and triggers the
secretion of pro-inflammatory cytokines and cytolytic prod-
ucts that can directly lyse and/or cause apoptosis of the
infected host cells. In models of mycobacterial infection
MAIT cells enhance the ability of macrophages to inhibit
the growth of intracellular organisms. Whether the primary
mechanism of control is through enhancing the ability of
macrophages to control infection or by killing infected cells
is unknown. The effector functions of MAIT cells in the
context of bacterial and mycobacterial infection appear to
rely in part on bacterially produced ligand being presented
by MR1, with cytokines produced in the context of infec-
tion potentiating MAIT cell effector functions (Figure 1).
Insights from animal experiments
MR1 is highly conserved among mammals, and although
mice have considerably lower levels of MAIT cells than
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humans, experiments using mice have provided some
insights into the role that MAIT cells may play in the
immune response to infections with MR1-ligand produ-
cing bacteria.3,4,35 These experiments make use of
transgenic mouse strains that over-express MAIT cells
(Va19i-Tg and Vb6-Tg), MR1 knock-outs (MR1-KO) of
the transgenic strains and wild-type C57BL/6 mice. These
models have allowed comparisons of the outcome of
experimental infection in mice with enhanced, intact or
disrupted MR1–MAIT cell axes. When exposed to the
same initial intraperitoneal inoculum, C57BL/6 MR1-KO
mice developed higher burdens of systemic infection with
Klebsiella pneumoniae and had decreased survival com-
pared with wild-type animals.36 This suggests that MR1
(and presumably MAIT cells) play a protective role and
aid in the containment of K. pneumoniae infection. Inter-
estingly, these findings were not replicated in similar
infections with three other Gram-negative organisms that
are known to produce MR1-ligands: E. coli, Shigella
dysenteriae and Yersinia enterocolitica. Another group
making use of the transgenic over-expressing MAIT cell
mice (both Va19i-Tg and Vb6T), found that MR1-KO
mice had higher bacterial burdens of both E. coli and
Mycobacterium abscessus than those with intact MR1.21
Sakala et al.37 recently compared outcomes in the Va19i-
Tg stain (and its MR1-KO) and C57BL/6 (and its MR1-
KO) after nasal aerosolized M. tuberculosis infection and
found that the MAIT over-expressing mice had the lowest
burden of infection and the MR1 KO mice had the high-
est. This growing body of evidence suggests that an intact
MAIT cell–MR1 axis may be protective against some (but
not all) bacterial infections with MR1-ligand producing
organisms.
Additional data suggest that the protective role of
MAIT cells in these infections probably occurs in the
early days after exposure to pathogen. Chua et al.34
demonstrated that MR1 KO mice had higher burdens of
pulmonary infection 10 days after aerosolized infection
with M. bovis, but that after 30 days there was no differ-
ence in the bacterial burden between the two groups.
Using intranasal infection with the live vaccine strain of
Francisella tularensis (LVS) in BL/6 wild-type and MR1-
KO mice, Meierovics et al.38 demonstrated that MAIT
cells appear to have a direct, early antibacterial effect in
the lungs and a sustained impact on the establishment of
an effective adaptive mucosal immune response. Specifi-
cally, they demonstrated that upon exposure to LVS
F. tularensis, MAIT cells, here defined as double-negative
T cells that were enriched for the canonical MAIT cell
TCR Va19-Ja33, accumulated in the lungs and were asso-
ciated with brisk production of IFN-c, TNF-a, IL-17A
and iNOS as well as significantly faster clearance of the
bacteria from the lungs. The authors explored the relative
contribution of MAIT cells and classical CD4+ and CD8+
T cells to bacterial control and investigated the impact of
MAIT cells on the classical adaptive immune response. In
mice depleted of classical CD4+ and CD8+ T cells but
with intact MR1, MAIT cells were able to control LVS
F. tularensis infection and establish a state of chronic
non-lethal infection for up to 2 months. In contrast, mice
depleted of both classical T cells and MR1/MAIT cells
died rapidly, suggesting that MAIT cells have the ability
to control infection for prolonged periods of time even in
the absence of conventional T cells. Importantly, in this
study the adaptive immune system was incapable of opti-
mal function in the absence of MR1 and MAIT cells. In
the MR1-KO mice, recruitment to the lungs of activated
IFN-c producing classical CD4+ and CD8+ T cells was
significantly delayed and attenuated with 60–80% fewer
conventional T cells recruited to the lungs at Day 8 fol-
lowing infectious challenge. Taken together these findings
suggest that MAIT cells are poised in the mucosal surface
of the airways and lungs, where they provide early control
of bacterial infection through production of pro-inflam-
matory cytokines and antimicrobial products (Fig. 2).
Additionally, during this period of early infection they are
required for the establishment of optimal adaptive
immune response. The mechanisms by which MAIT cells
lay the ground work for later adaptive immunity is
unknown.
Insights from study of human cohorts
In one of the first studies of MAIT cells in human dis-
ease, Gold et al.20 demonstrated that M. tuberculosis-reac-
tive MR1-restricted T cells were found in the peripheral
circulation of all the people that they assessed, including
those who had no evidence of previous exposure to
M. tuberculosis. Interestingly, these innately M. tuberculosis-
reactive T cells were found at much lower levels in those
individuals with active tuberculosis (compared with those
with no history of exposure, or those with evidence of
latent infection). Other studies have confirmed that MAIT
cell frequencies are decreased during active tuberculosis
(and non-tuberculosis mycobacterial lung disease) in
diverse geographic settings.11,21,33,39 Peripheral depletion
of MAIT cells is not, however, disease specific, with low
levels of peripheral MAIT cells found in individuals with
cystic fibrosis experiencing pulmonary exacerbations due
to Pseudomonas aeruginosa,40 non-streptococcal sepsis41
and cholera.42 There is evidence that the degree of
peripheral MAIT depletion may correlate with disease
severity and may be reversed with antibiotic treatment
during recovery from illness.11,39–41 Interestingly, in a
study of peripheral MAIT cells in intensive care unit
patients with sepsis, failure of peripheral MAIT cells to
rise during the intensive care unit stay was correlated
with the subsequent acquisition of secondary infections.41
Depletion of MAIT cells in the peripheral blood is not
specific to bacterial infection and is also observed in
ª 2016 John Wiley & Sons Ltd, Immunology, 150, 45–54 47
REVIEW SERIES: MAIT CELLS-LIGANDS AND FUNCTIONS


















































Two pathways to MAIT cell activation





MAIT cell Infected cell
ª 2016 John Wiley & Sons Ltd, Immunology, 150, 45–5448
REVIEW SERIES: MAIT CELLS-LIGANDS AND FUNCTIONS
E. B. Wong et al.
infections due to non MR1-ligand producing organisms
(i.e. viral infections, discussed below) and non-infectious
states of disease including autoimmunity, asthma, obesity
and diabetes (beyond the scope of this article).43–46
The mechanism for depletion of peripheral MAIT cells
during active bacterial infections is unknown. Although
MAIT cells are named for their enrichment in the gut
mucosa, there are very few human data about mucosal
MAIT cells during bacterial infections that would allow
assessment of the hypothesis that peripheral depletion is
due to redistribution of MAIT cells to the site of disease.
Mycobacterium tuberculosis-reactive MAIT cells were
found in healthy uninfected lung tissue by Gold et al.20
and MAIT cells were found to be present in two M. tu-
berculosis-infected lungs by LeBourhis et al.21 without
control tissue or paired peripheral sample available for
comparison. LeBourhis et al.21 reported enrichment of
MAIT cells in the ascites fluid from a single patient with
tuberculosis peritonitis, but in a larger series, Jiang et al.33
found diminished frequencies of MAIT cells in pleural
fluid from patients with tuberculosis pleuritis and non-
enriched levels of MAIT cells in the peritoneal fluid of
patients with tuberculosis peritonitis. Hence, it is not
clear whether MAIT cell depletions in bacterial infections
are due to redistribution to mucosal sites.
The few MAIT cells that remain in circulation during
active pulmonary tuberculosis have diminished functional
capacity, producing less IFN-c upon stimulation and
decreased transcription of effector genes (IFN-c, TNF-a,
IL-17F, granulysin and granzyme B).33,39 These function-
ally impaired MAIT cells express higher levels of
pro-apoptotic markers and higher levels of the inhibitory
co-stimulating molecule programmed death-1 (PD-1)
than MAIT cells from non-tuberculous patients.33,39,47 In
vitro blockade of PD-1 can increase IFN-c production in
circulating MAIT cells from patients with tuberculosis.33
In summary, human data provide little indication
about the role that MAIT cells are playing in bacterial
infectious disease, but do demonstrate that during active
bacterial infections MAIT cells become depleted from the
peripheral blood and those that remain display a dysfunc-
tional phenotype. Using the mouse model, Sakala et al.37
found that peripheral MAIT cells up-regulate integrins
and cell trafficking molecules to migrate to the lungs
soon after aerosolized mycobacterial infection. Given that
the animal data suggest migration of peripheral MAIT
cells to the lung upon respiratory exposure and protective
activity of MAIT cells in the lungs, the lack of human
data about the role of MAIT cells at mucosal sites during
bacterial infection is a considerable gap in the field.
Fungal infections
Candida albicans and Candida glabrata both have intact
riboflavin synthesis pathways and have both been shown
to activate MAIT cells in vitro.21 Other fungal pathogens
have not been evaluated. Gold et al.13 compared the
T-cell receptor repertoire of C. albicans-reactive MAIT
cells to M. smegmatis-reactive or S. typhimurium-reactive
MAIT cells and found that the C. albicans-reactive MAIT
TCR repertoire appeared to be less diverse than the reper-
toires of cells reactive to the other two pathogens. The
authors hypothesize that this might be due to previous
expansion of C. albicans-reactive MAIT cell clonotypes in
response to specific MR1-restricted ligands from this rela-
tively ubiquitous commensal. The clinical significance of
MAIT cells in commensal fungal colonization or in
pathogenic fungal infection has not been investigated in
either animal models or human cohorts. Whether other
pathogenic fungi have the capacity to activate MAIT cells
in vitro or engage MAIT cells in vivo is also unknown.
Viral infections
In contrast to many bacterial and fungal pathogens,
viruses lack the metabolic pathways to synthesize ribofla-
vin and therefore do not produce MAIT cell activating
MR1 ligands. Indeed, in vitro infection of antigen-pre-
senting cells with a panel of viruses (including
encephalomyocarditis virus, Sendai virus, Newcastle dis-
ease virus, herpes simplex virus and parainfluenza 3
virus) failed to activate MAIT cells directly.21 Recently,
however, a report by van Wilgenburg et al.48 has demon-
strated that MAIT cells can be activated in an MR1-inde-
pendent cytokine-driven manner by dengue virus,
hepatitis C virus and influenza virus. Interleukin-18 sig-
nalling is most central to MAIT activation in these set-
tings, though the effects of other virally driven cytokines
Figure 1. Mucosal-associated invariant T (MAIT) cell activation and activities in the setting of infection. (a) Infected cells activate MAIT cells by
two independent pathways. (1) Bacteria produce small molecule vitamin B metabolites that are loaded onto MR1 and presented on the surface of
the infected cell. The semi-invariant MAIT cell T-cell receptor ab (TCR-ab) binds the MR1–ligand complex resulting in TCR-dependent MAIT
cell activation. (2) Alternatively, or additionally, cytokines produced by infected cells, including interleukin-12 (IL-12), IL-15, IL-18 and IL-7 can
activate MAIT cells through cytokine receptors. (b) Upon activation, MAIT cells perform anti-bacterial effector functions. Rapidly, they release
effector molecules including (1) cytokines [including interferon-c (IFN-c), tumour necrosis factor-a (TNF-a) and possibly IL-17] and (2) cytoly-
tic products (including granzymes and perforin). In the tissue environment these may result in the activation of innate immune cells, lysis of
infected cells, direct killing of bacteria, and recruitment of other immune cells to the site of infection. (3) MAIT cell activation may result in local
proliferation and/or (4) apoptosis of individual MAIT cell clones both of which may potentially shape the tissue-resident TCR repertoire.
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Figure 2. Mucosal-associated invariant T (MAIT) cells during bacterial and viral infection. In a state of health (left panel), MAIT cells are abun-
dant in the circulation, comprising 1–10% of CD3+ lymphocytes and are present in both respiratory and gut mucosa. The relationship of MAIT
cells to commensal microbial populations in the gut and upper airway and the extent to which MAIT cell populations are tissue-specific is not
well understood, but they are likely to contribute to innate anti-bacterial defences at both sites. During local bacterial infection (i.e. pulmonary
tuberculosis, middle panel) MAIT cells may become enriched at the site of infection and possibly contribute to the early anti-bacterial immune
response. Circulating MAIT cells become depleted and the remaining population is activated, exhausted and dysfunctional. There is some evi-
dence that this may be reversible after the infection resolves. It is unknown what impact infection at one mucosal surface has on MAIT cells at a
distant site, i.e. the impact of pulmonary infection on gut MAIT cells or vice versa. During systemic viral infection [i.e. human immunodeficiency
virus (HIV) infection, right panel], MAIT cells in the peripheral circulation are irreversibly depleted and those remaining in circulation are acti-
vated, exhausted and dysfunctional. It is hypothesized that this may be driven by microbial translocation across a damaged gut epithelium leading
to activation-induced death of MAIT cells systemically. Alternatively, MAIT cells may redistribute to other mucosal surfaces. The impact of
altered microbial populations in the gut is unknown. To date there are no data on the impact of HIV on MAIT cells in the human lung.
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including IL-12, IL-15 and IFN-a/b also contributes. It
has long been apparent that chronic viral infections, espe-
cially human immunodeficiency virus (HIV) and hepatitis
C virus (HCV), appear to alter human MAIT cells signifi-
cantly by unclear mechanisms, so these new results may
shed light on the altered role of MAIT cells during viral
infections.
HIV
Investigations of MAIT cells from several cohorts of
HIV-infected people from around the world (USA, Eur-
ope, South Africa and Australia) have shown that people
with chronic HIV infection have significantly lower
levels of peripheral MAIT cells than comparable healthy
controls.49–54 Interestingly, the degree of MAIT cell
depletion does not correlate to the usual markers of
HIV disease progression, including the degree of periph-
eral CD4+ T-cell depletion or the level of viral replica-
tion in the blood (HIV viral load).51,54 Even individuals
who appear to have a natural ability to control HIV
infection (long-term non-progressors and elite con-
trollers) have been found to experience similar levels of
MAIT cell depletion to those observed in people with
chronic progressive HIV infection.50 Leeansyah et al.26,53
have found that the MAIT cells that remain in the
peripheral circulation of patients with HIV are function-
ally impaired compared with MAIT cells from healthy
people. Upon bacterial stimulation, they have found that
MAIT cells from people with untreated chronic HIV
produce lower levels of effector cytokines (IFN-c, TNF-a,
IL-17) and cytolytic products (granzyme A, granzyme B,
CD107a and perforin) upon stimulation with bacterial
MR1 ligand.26,53 Interestingly, these authors have found
that in vitro treatment with IL-7 has the capacity to
restore the cytolytic response to bacterial exposure in
MAIT cells from HIV-infected people.26 In contrast, Fer-
nandez et al.55found that MAIT cells from individuals
with chronic untreated HIV retained comparable levels
of IFN-c and TNF-a production upon stimulation with
purified MR1 ligand. The contrasting findings about the
functionality of residual MAIT cell populations may be
due to differences in the functional assays used by each
group. Fernandez et al. stimulated MAIT cells from
HIV-positive patients with an hMR1 over-expressing cell
line that had been pulsed with purified synthetic MAIT
cell activating antigen. In contrast, Leeansyah et al.26,53
stimulated peripheral blood mononuclear cells with
paraformaldehyde-fixed whole E. coli. Differences in the
strength of stimulation and cytokine co-stimulation or
inhibition may explain the discrepant findings. At this
point, therefore, there is consensus in the finding of
MAIT cell depletion but lack of consensus on the func-
tional capacity of those MAIT cells that remain in circu-
lation in patients with chronic HIV (Figure 2).
MAIT cell depletion appears to occur very early
(within the first few weeks) after HIV infection.49,54,55
To date there have been no animal or human studies
following individuals longitudinally before and after HIV
infection to address the possibility that individuals with
pre-existing low levels of peripheral MAIT cells are more
likely to become HIV infected. Nonetheless, the leading
hypothesis in the field is that events surrounding acute
HIV infection result in peripheral MAIT cell depletion.
Circulating MAIT cells express high levels of CCR5,
which is the co-receptor that facilitates HIV entry into
CD4+ T cells. However, Cosgrove et al.49 performed
in vitro infections with a CCR5-trophic HIV strain and
found that peripheral MAIT cells are no more likely to
be directly infected by HIV than other T cells. Finding
that E. coli exposure induced caspase-3-mediated apopto-
sis in MAIT cells, they proposed that translocation of
microbial products due to injury to the intestinal
mucosa during acute HIV infection could result in
uncontrolled activation and activation-induced MAIT cell
death.49 In support of this hypothesis, which was also
put forth by Leeansyah et al.53, activation markers
(CD38 and HLA-DR) are elevated on MAIT cells from
HIV-infected individuals compared with healthy controls
and levels of MAIT cell activation inversely correlate
with MAIT cell frequency.50,51,56 Despite the fact that
multiple groups have put forward the hypothesis that
MAIT cell depletion is due to microbial translocation,
no study to date has directly linked plasma markers of
microbial translocation to MAIT cell loss or dysfunction.
An alternative, and perhaps related, hypothesis to explain
the absence of peripheral MAIT cells in HIV is that they
redistribute to mucosal sites and become sequestered
there. The human data on non-peripheral MAIT cells in
HIV are very limited. Eberhard et al.50 found that MAIT
cells were reduced in the lymph nodes of HIV patients
compared with uninfected controls. MAIT cell levels in
the colon have been assessed by three groups and were
also found to be lower in HIV-infected compared with
uninfected people during chronic infection.49,52,53
Recently, human MR1-5-OP-RU tetramers were used to
evaluate MAIT cell distribution in simian immunodefi-
ciency virus-infected rhesus macaques. Although limited
by lack of species-specific reagents, this study found low
frequencies of MAIT cells in all examined tissue sites
(peripheral blood, liver, mesenteric lymph nodes, jeju-
num and bronchoalveolar lavage) of simian immunodefi-
ciency virus-infected animals.57 There are therefore
currently no data to support the redistribution hypothe-
sis; however, with only two non-blood sites having been
investigated to date human data are limited.
Studies suggest that otherwise effective antiretroviral
therapy that suppresses HIV viral load and restores
peripheral CD4+ T cells does not appear to restore cir-
culating MAIT cell frequencies.49,50,53,54,58,59 Greathead
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et al.52 have reported that colonic MAIT cells were
restored to levels comparable to those of healthy con-
trols after long term ART. Although there is no consen-
sus about the effect of HIV on residual MAIT cell
function, the group that reported that cytokine and
cytolytic function decreased during chronic untreated
HIV infection has found that antiretroviral therapy par-
tially restores functional capacity.53 Importantly there
has been a single report of a patient who received
antiretroviral therapy very early after HIV infection (Fie-
big Stage III) who had relatively preserved MAIT fre-
quencies.50
In summary, HIV infection is associated with early and
largely irreversible depletion of MAIT cells from the
peripheral circulation. The mechanism for this depletion
is currently unknown and does not appear to be direct
viral infection. Whether or not this peripheral depletion
is reflective of universal MAIT cell depletion or whether
it may be due to redistribution to mucosal sites has not
been definitively addressed, although there is some
intriguing data indicating that mucosal MAIT cells may
be more responsive to antiretroviral therapy than circulat-
ing MAIT cells. The impact that HIV-induced MAIT cell
alterations have on overall immune function is unknown.
Gaardbo et al.60 have found that low MAIT cells are asso-
ciated with a constellation of immunological and meta-
bolic derangements that are linked to immune activation
and poor outcomes, but the specific role of MAIT cells in
this is unclear. Based on the previous discussion of the
role of MAIT cells as pre-armed mucosal effectors that
respond to bacterial and fungal infections early and con-
tribute to the eventual quality of the adaptive immune
response, it is hypothesized that derangements of normal
MAIT cell frequencies, function and distribution in HIV
may play a role in the increased vulnerability to mucosal
bacterial and fungal infections that is seen both early in
and throughout the course of HIV disease. Assessing this
hypothesis and determining mechanisms and potential
strategies for intervention are critical next steps for the
field.
MAIT cells and viral hepatitis
MAIT cells are significantly enriched in the liver, where
they have been found to comprise up to 50% of
liver-resident lymphocytes. They are found primarily in
the biliary tract and in the context of liver infection can
be activated by MR1-presented bacterial ligand or indi-
rectly via IL-12 and IL-18 produced by antigen-presenting
cells in response to Toll-like receptor 8 signalling trig-
gered by viral RNA.18,61 Jo et al.18found that MAIT cells
were enriched in normal and chronically hepatitis B
virus-infected livers but were relatively depleted in end-
stage liver disease. Billerbeck et al.17 found that
CD161++ CD8+ cells (probably MAIT cells) had higher
capacity for IL-17 and IL-22 production in the liver com-
pared with the peripheral blood and that dual functional-
ity (ability to co-express IL-17 and IFN-c upon
stimulation) of these cells was inversely correlated with
clinical disease score in chronic untreated hepatitis C. In
the peripheral compartment, Barathan et al.62 found that
patients with chronic HCV had lower MAIT cells fre-
quencies compared with healthy controls. Likely reflecting
a state of chronic inflammation and infection, MAIT cells
in these patients had higher levels of markers of activa-
tion and exhaustion (HLA-DR, CD38, PD-1, TIM-3 and
CTLA-4) compared with healthy controls. van Wilgen-
burg et al.48 confirmed the finding that people with
chronic HCV infection have depleted and activated
peripheral MAIT cell populations; and interestingly
demonstrated that MAIT cells have the ability to inhibit
HCV replication in an IFN-c-dependent manner. As dis-
cussed above, in patients with HIV infection, peripheral
MAIT cell depletions are not improved by otherwise
effective antiretroviral therapy. Two recent studies in
HCV-infected patients have similarly found that the
MAIT cell depletion and dysfunction observed in chronic
HCV is not reversible even after successful interferon
therapy or interferon-free therapy.63,64 The role of MAIT
cells in liver inflammation and the impact of MAIT cell
perturbations on the general state of mucosal immunity
in patients with these infections require further investiga-
tion.
What we know and what remains unknown
Before the discovery of the nature of the MAIT cell
antigen, it was a mystery how and why individual MAIT
cell clones could respond to cells infected with multiple
different bacterial and fungal organisms (E. coli, Kleb-
siella, M. tuberculosis and C. albicans) but not react at all
to cells infected with other bacterial species (Streptococcus
pyogenes and Enterococcus faecalis) or viruses. The discov-
ery that organisms that synthesize riboflavin produce
metabolic intermediates that activate MAIT cells has sig-
nificantly advanced our understanding of this abundant
class of unconventional T cells. At this stage, however,
many critical questions about the role of MAIT cells in
the response to infection and in the pathogenesis of infec-
tious disease remain. Increasing in vitro and mouse model
evidence suggests that MAIT cells play a protective role
against bacterial and mycobacterial infections. They
appear to act as pre-armed pro-inflammatory and cytoly-
tic effectors that have the capacity to lyse infected cells
and control bacterial growth in the early days after infec-
tion.65–70 They may also, like other tissue-resident uncon-
ventional cells including natural killer T and innate
lymphoid cells, play an important role in setting the stage
for the establishment of a coordinated adaptive immune
response to infection.
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As has been discussed, human data on MAIT cells in
infectious diseases is currently very limited. The distribu-
tion of MAIT cells in human mucosal sites and the
impact of healthy and diseased microbiota on human
MAIT cells are unknown. The role of MAIT cells in res-
piratory and gastrointestinal viral infections, all human
fungal infections, and parasitic infections is also
unknown. To date, when MAIT cells have been studied
outside the peripheral circulation, attention has mostly
focused on respiratory or gut-resident MAIT cells.
Recently, however, MAIT cells have been shown to have
a distinct functional profile in the female genital
mucosa.30 It is likely that MAIT cells are also present in
the urinary and male genital tracts, although these have
not yet been explored. MAIT cells have been found in
the central nervous system in the setting of neoplasm as
well as multiple sclerosis.71–73 The potential role of MAIT
cells in immunoprotection or immunopathology of infec-
tions of these various anatomical sites is not currently
known but is important to understand. Even in the
human diseases that have been most studied to
date – HIV and mycobacterial infections – there is little
understanding of the reasons for or the immunological
consequences of the widely observed peripheral MAIT
cell depletions. New tools, including synthetic MAIT
ligands, MR1 tetramers and next-generation TCR
sequencing have recently been added to the toolbox avail-
able to MAIT cell immunologists and will hopefully
accelerate research into these fundamental questions. As
the most abundant class of donor-unrestricted T cells in
humans, MAIT cells represent a potentially attractive tar-
get for immunotherapy or T-cell vaccines.74–76 To
advance towards this exciting possibility, however, the
field will first need to answer the fundamental questions
about the role that MAIT cells play in the protection
against and the pathogenesis of infectious diseases.
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